151 related articles for article (PubMed ID: 10557074)
1. Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor.
Ishii N; Tada M; Hamou MF; Janzer RC; Meagher-Villemure K; Wiestler OD; Tribolet N; Van Meir EG
Oncogene; 1999 Oct; 18(43):5870-8. PubMed ID: 10557074
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
Ständer M; Peraud A; Leroch B; Kreth FW
Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.
Peraud A; Kreth FW; Wiestler OD; Kleihues P; Reulen HJ
Clin Cancer Res; 2002 May; 8(5):1117-24. PubMed ID: 12006527
[TBL] [Abstract][Full Text] [Related]
4. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
[TBL] [Abstract][Full Text] [Related]
5. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood.
Pollack IF; Hamilton RL; Finkelstein SD; Campbell JW; Martinez AJ; Sherwin RN; Bozik ME; Gollin SM
Cancer Res; 1997 Jan; 57(2):304-9. PubMed ID: 9000573
[TBL] [Abstract][Full Text] [Related]
6. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.
Watanabe K; Sato K; Biernat W; Tachibana O; von Ammon K; Ogata N; Yonekawa Y; Kleihues P; Ohgaki H
Clin Cancer Res; 1997 Apr; 3(4):523-30. PubMed ID: 9815715
[TBL] [Abstract][Full Text] [Related]
7. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion.
Fulci G; Ishii N; Maurici D; Gernert KM; Hainaut P; Kaur B; Van Meir EG
Cancer Res; 2002 May; 62(10):2897-905. PubMed ID: 12019170
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutations in astrocytic gliomas: an association with histological grade, TP53 codon 72 polymorphism and p53 expression.
Faria MH; Neves Filho EH; Alves MK; Burbano RM; de Moraes Filho MO; Rabenhorst SH
APMIS; 2012 Nov; 120(11):882-9. PubMed ID: 23009112
[TBL] [Abstract][Full Text] [Related]
9. p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression.
van Meyel DJ; Ramsay DA; Casson AG; Keeney M; Chambers AF; Cairncross JG
J Natl Cancer Inst; 1994 Jul; 86(13):1011-7. PubMed ID: 8007011
[TBL] [Abstract][Full Text] [Related]
10. Molecular markers relating to malignant progression in Grade II astrocytoma.
Yue WY; Yu SH; Zhao SG; Chen ZP
J Neurosurg; 2009 Apr; 110(4):709-14. PubMed ID: 19025355
[TBL] [Abstract][Full Text] [Related]
11. Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts.
Jones DT; Mulholland SA; Pearson DM; Malley DS; Openshaw SW; Lambert SR; Liu L; Bäcklund LM; Ichimura K; Collins VP
Acta Neuropathol; 2011 Jun; 121(6):753-61. PubMed ID: 21327941
[TBL] [Abstract][Full Text] [Related]
12. p53 abnormality and tumor invasion in patients with malignant astrocytoma.
Momota H; Narita Y; Matsushita Y; Miyakita Y; Shibui S
Brain Tumor Pathol; 2010 Oct; 27(2):95-101. PubMed ID: 21046311
[TBL] [Abstract][Full Text] [Related]
13. Ethnicity delineates different genetic pathways in malignant glioma.
Chen P; Aldape K; Wiencke JK; Kelsey KT; Miike R; Davis RL; Liu J; Kesler-Diaz A; Takahashi M; Wrensch M
Cancer Res; 2001 May; 61(10):3949-54. PubMed ID: 11358811
[TBL] [Abstract][Full Text] [Related]
14. Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors.
Mangerel J; Price A; Castelo-Branco P; Brzezinski J; Buczkowicz P; Rakopoulos P; Merino D; Baskin B; Wasserman J; Mistry M; Barszczyk M; Picard D; Mack S; Remke M; Starkman H; Elizabeth C; Zhang C; Alon N; Lees J; Andrulis IL; Wunder JS; Jabado N; Johnston DL; Rutka JT; Dirks PB; Bouffet E; Taylor MD; Huang A; Malkin D; Hawkins C; Tabori U
Acta Neuropathol; 2014 Dec; 128(6):853-62. PubMed ID: 25315281
[TBL] [Abstract][Full Text] [Related]
15. Telomerase activity and alterations in telomere length in human brain tumors.
Hiraga S; Ohnishi T; Izumoto S; Miyahara E; Kanemura Y; Matsumura H; Arita N
Cancer Res; 1998 May; 58(10):2117-25. PubMed ID: 9605755
[TBL] [Abstract][Full Text] [Related]
16. Clonal expansion of p53 mutant cells is associated with brain tumour progression.
Sidransky D; Mikkelsen T; Schwechheimer K; Rosenblum ML; Cavanee W; Vogelstein B
Nature; 1992 Feb; 355(6363):846-7. PubMed ID: 1311419
[TBL] [Abstract][Full Text] [Related]
17. Expression of p53 and prognosis in children with malignant gliomas.
Pollack IF; Finkelstein SD; Woods J; Burnham J; Holmes EJ; Hamilton RL; Yates AJ; Boyett JM; Finlay JL; Sposto R;
N Engl J Med; 2002 Feb; 346(6):420-7. PubMed ID: 11832530
[TBL] [Abstract][Full Text] [Related]
18. Role of TP53 in the progression of pre-malignant and malignant oral mucosal lesions. A follow-up study of 144 patients.
Ogmundsdóttir HM; Björnsson J; Holbrook WP
J Oral Pathol Med; 2009 Aug; 38(7):565-71. PubMed ID: 19473450
[TBL] [Abstract][Full Text] [Related]
19. Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas.
Qu M; Olofsson T; Sigurdardottir S; You C; Kalimo H; Nistér M; Smits A; Ren ZP
Acta Neuropathol; 2007 Feb; 113(2):129-36. PubMed ID: 17031656
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
Karamurzin Y; Leitao MM; Soslow RA
Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
